Please assess the completion status of the following clinical trial:

Trial Title: Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients may be included in the study only if they meet all the following criteria:~1. Histologically proven diagnosis of soft tissue sarcoma.~2. Advanced unresectable or metastatic soft tissue sarcoma not previously treated with chemotherapy for metastatic disease.~3. At least one measurable lesion according to RECIST1.1 criteria.~4. Availability of a tumor sample (primary and/or metastatic sites).~5. Age ≥ 70 years (70-75 years if UNFIT at G8; \>75 independent of G8 score)~6. ECOG PS 0-2.~7. Life expectancy of at least 12 weeks.~8. Neutrophils ≥1.5 x 109/L, Platelets ≥100 x 109/L, Hgb ≥ 9 g/dl.~9. Adequate hepatic function, defined as: Total bilirubin ≤ 1.5 time the upper-normal limits (ULN) of the normal values, ASAT (SGOT) and/or ALAT (SGPT) ≤ 2.5 x ULN (or \<5 x ULN in case of liver metastases)~10. Alkaline phosphatase ≤ 2.5 x ULN (or \<5 x ULN in case of liver metastases).~11. Creatinine clearance ≥ 30 mL/min.~12. Normal cardiac function, with left ventricular ejection fraction (LVEF) ≥50%.~13. Male subjects with female partners of childbearing potential must be willing to use adequate contraception as approved by the investigator~14. Geriatric assessment by means of G8 screening tool and CRASH score.~15. Will and ability to comply with the protocol.~16. Written informed consent to study participation.~Exclusion Criteria:~* Patients will be excluded from the study for any of the following reasons:~  1. Previous treatment for metastatic disease.~ 2. Previous (neo) adjuvant chemotherapy with anthracyclines.~ 3. Radiotherapy to any site within 4 weeks before the study.~ 4. Untreated brain metastases or spinal cord compression or primary brain tumors.~ 5. Active uncontrolled infections or other clinically relevant concomitant illness contraindicating chemotherapy administration.~ 6. Clinically significant (i.e. active) cardiovascular disease for example cerebrovascular accidents (≤6 months), myocardial infarction (≤6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF), serious cardiac arrhythmia requiring medication.~ 7. Treatment with any investigational drug within 30 days prior to enrollment or 2 investigational agent half-lives (whichever is longer)~ 8. Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of localized basal and squamous cell carcinoma or cervical cancer in situ.~ 9. Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to take oral medication.~ 10. Known hypersensitivity to trial drugs or hypersensitivity to any other component of the trial drugs.~ 11. Any concomitant drugs contraindicated for use with the trial drugs according to the product information of the pharmaceutical companies.~ 12. Sexually active males unwilling to practice contraception during the study and until 6 months after the last trial treatment.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metronomic cyclophosphamide (Type: EXPERIMENTAL): Cyclophosphamide 50 mg daily per os continuously; Patients will be visited for re-cycling every three weeks. Metronomic cyclophosphamide will be taken in the morning along with a full glass of water.
- Doxorubicin (Type: ACTIVE_COMPARATOR): Doxorubicin 60 mg/mq i.v. in 10 minutes, day 1; to be repeated every three weeks up to a maximum of 6 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).